Gutman M, Ravia Y, Assaf D, Yamamoto T, Rozin R, Shiloh Y
Department of Surgery, Rokach Hospital, Tel-Aviv, Israel.
Int J Cancer. 1989 Nov 15;44(5):802-5. doi: 10.1002/ijc.2910440509.
Molecular probes for cellular proto-oncogenes have recently been extensively used in order to search for functional and structural alterations in tumor tissues. Variable, and sometimes contradictory, results have been obtained regarding the frequency and clinical significance of amplification of the c-myc and c-erbB-2 proto-oncogenes in different series of human solid tumors. We addressed this question by performing Southern blotting analysis on 131 primary adult solid tumors of various tissues and 5 metastases of unknown origin, using molecular probes for both genes. Amplification of c-myc was found in 5 of the primary tumors, and amplification of c-erbB-2 in 5 others. In 2 tumors of the latter group, the c-erbB-2 gene was also rearranged. The distribution of these 10 tumors with regard to clinical stage and course of the disease did not point to an association between the amplification events and specific stage or prognosis. We concluded that, in this series, the amplification of both proto-oncogenes was occasional and was not a prognostic marker.
为了探寻肿瘤组织中的功能和结构改变,细胞原癌基因的分子探针最近得到了广泛应用。关于不同系列人类实体瘤中c-myc和c-erbB-2原癌基因扩增的频率及临床意义,已获得了多样且有时相互矛盾的结果。我们通过对131例不同组织的成人原发性实体瘤及5例来源不明的转移瘤进行Southern印迹分析来解决这个问题,使用了针对这两个基因的分子探针。在5例原发性肿瘤中发现了c-myc扩增,在另外5例中发现了c-erbB-2扩增。在后一组的2例肿瘤中,c-erbB-2基因也发生了重排。这10例肿瘤在临床分期和疾病进程方面的分布并未表明扩增事件与特定分期或预后之间存在关联。我们得出结论,在这个系列中,这两个原癌基因的扩增是偶然的,并非预后标志物。